Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
Eli Lilly (NYSE: LLY) signed a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharma focused on rapid-acting neuroplastogens for mental health. AtaiBeckley’s lead asset, BPL-003, an intranasal synthetic 5-MeO-DMT for treatment-resistant depression, is in Phase 3 preparation and holds FDA Breakthrough Therapy Designation.
Lilly will pay $6.75 per share in cash at closing, plus up to $2.50 per share via a contingent value right tied to specified milestones for BPL-003 and VLS-01. The upfront consideration values AtaiBeckley’s equity at about $2.8 billion, with CVRs representing up to an additional $1.0 billion. The cash offer reflects a ~40% premium to AtaiBeckley’s 30-day VWAP through July 15, 2026. The deal is expected to close in the third quarter, subject to AtaiBeckley stockholder and regulatory approvals; it is not subject to a financing condition. About 15% of AtaiBeckley shares are already locked up through voting and support agreements.
AtaiBeckley (NASDAQ: ATAI) has dosed the last patient in Elumina, its Phase 2b trial of VLS-01 for treatment-resistant depression, with 156 patients randomized 1:1. Topline data are anticipated in Q4 2026.
The company plans a Phase 3 program in major depressive disorder, with generalized anxiety disorder as a potential follow-on, and positions VLS-01 alongside BPL-003 to address mood and anxiety disorders.
AtaiBeckley (NASDAQ: ATAI), a clinical-stage mental health biotech, will be added to the Russell 2000 and Russell 3000 indexes at the U.S. market open on June 29, 2026, as part of the first 2026 Russell reconstitution.
Approximately $12.2 trillion is benchmarked to Russell U.S. indexes. The addition follows AtaiBeckley’s recent inclusion in the S&P Total Market, S&P Completion, and CRSP U.S. benchmark indexes, further broadening its visibility across major U.S. equity benchmarks.
AtaiBeckley (NASDAQ: ATAI), a clinical-stage mental health biotech, launched a Patient Impact Grant Program offering three $20,000 grants to non-profit, mission-driven organizations. Funding targets community support, education and stigma reduction, and ecosystem innovation and independent research in mental health.
A review panel including AtaiBeckley leaders and an external expert from Mental Health America will select recipients. Applications are open now and close on September 1.
AtaiBeckley (NASDAQ: ATAI) will participate in several investor conferences in June 2026, including events hosted by Jefferies, Oppenheimer, HCW and UBS, featuring fireside chats, presentations and one-on-one meetings.
Live and archived webcasts will be accessible via AtaiBeckley’s investor relations website.
AtaiBeckley (NASDAQ: ATAI) reported Q1 2026 results and a pipeline update. Cash, cash equivalents and short-term securities were $209.9 million, expected to fund operations into 2029, including anticipated BPL-003 Phase 3 topline readouts.
BPL-003 for treatment-resistant depression is on track to start a two‑study Phase 3 program in Q2 2026. VLS-01 Phase 2 topline results are anticipated in Q4 2026, and EMP-01 Phase 2a data showed improvements across multiple social anxiety measures. R&D and G&A increased, driving a $29.8 million net loss.
AtaiBeckley (NASDAQ: ATAI) received the Silver Award in OVID Health’s 2026 Patient Participant Index for its multiyear collaboration with PsyPAN to integrate participant insights into psychedelic clinical research.
Highlights include 2023 co‑designed qualitative workshops, the white paper “The Participants in Their Own Words,” a 12‑month unrestricted grant enabling a 2025 peer‑support pilot, and expanded academic and international advocacy partnerships.
AtaiBeckley (NASDAQ: ATAI) reported peer‑reviewed Phase 2a results showing a single intranasal dose of BPL‑003 produced a 66.7% antidepressant response rate by Day 2 in SSRI‑concomitant TRD patients (n=12) and durable responses at Day 85: 83% (10 mg) and 66.7% (12 mg).
FDA Breakthrough Therapy designation granted Oct 2025; Phase 3 initiation is on track for Q2 2026 following FDA End‑of‑Phase 2 alignment.
AtaiBeckley (NASDAQ: ATAI) was added to the S&P Total Market Index, S&P Completion Index and CRSP U.S. benchmark indices, effective March 23, 2026. Inclusion in CRSP triggers mandatory position-building by passive index funds tracking more than $3 trillion in assets.
The company said its BPL-003 Phase 3 program remains on track to initiate in Q2 2026, with topline VLS-01 Phase 2b data expected in H2 2026. These additions follow inclusion in the Nasdaq Biotechnology Index in December 2025.
AtaiBeckley (NASDAQ: ATAI) reported peer-reviewed Phase 2a Cohort 1 results for BPL-003 in treatment-resistant depression (TRD). A single 10 mg intranasal dose produced a mean MADRS reduction of 12.6 points by Day 2 (27.5 to 14.8), sustained to Day 85 (14.5).
Response rate ≥50% was 54.5% through Day 85; 63.6% achieved remission at one or more timepoints. SHAPS improved from 8.4 to 1.5. No serious adverse events or withdrawals were reported. Phase 3 remains on track to initiate in Q2 2026 after a successful EOP2 meeting.